1. Scrip
  2. >>Business
  3. >>Strategy

Moderna Reports ‘Robust’ Response From COVID-19 Booster Shots

Pipeline Sees Continued Progress, Helped By Vaccine Windfall

 
• By Alaric DeArment

Executives said the company was “capacity constrained” for 2021 and not taking further mRNA-1273 vaccine orders for delivery this year.

Moderna vaccine
Moderna's COVID-19 vaccine provided the company with a huge windfall as it registered a $2.3bn profit • Source: Shutterstock

With proof of concept in the form of its wildly successful vaccine against SARS-CoV-2 infection, Moderna, Inc.is now taking its messenger RNA show on the R&D road as it reports progress in its platform in infectious diseases apart from COVID-19 and beyond infectious diseases as well. However, the pandemic still looms large for the company, which also released data showing that booster shots of its vaccine produced strong immune responses against the coronavirus.

The Cambridge, MA-based company announced its second quarter 2021 earnings 5 August, reporting total revenue of $4.4bn, a 6,467% increase from the second quarter of 2020, due primarily to $4.2bn in sales of the company’s COVID-19 vaccine, mRNA-1273. (Also see "Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals" - Scrip, 5 August, 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.